▟ Vinebot intrinsic value, daily

← back

IEX IDEX Corporation

industrial · valued with opus medium conviction · deep-dived 2026-11-17

HOLD
Intrinsic value$114.54
Price (at call)$233.57
Margin of safety -51.0%
vs market (rating basis) -14.2%

High-quality niche compounder, but at 30x earnings the market already pays for full recovery.

The story

IDEX is a portfolio of niche, engineered flow-control, precision-instrument and fire/safety businesses that sell mission-critical, specified-in components with high switching costs and strong aftermarket pull. It is a mature serial acquirer: organic growth tracks industrial GDP plus pricing, and M&A adds a few points a year. Recent margin compression reflects the industrial destocking cycle and acquisition amortization, not a broken franchise. Revenue is now re-accelerating as its life-science and semiconductor exposure recovers.

TTM revenue is up about 6% and the margin is 20.9%. I set margins to recover toward 24%, roughly the 2021-2022 level and IDEX's long-run adjusted economics, rather than staying at the trough. Reported sales-to-capital of 0.63 is weighed down by goodwill from past acquisitions, so I use a marginal 1.6 that blends capital-light organic growth with ongoing bolt-on deals. The 10-year horizon fits a durable niche moat, but the moat is not wide enough to justify 15 years.

Value drivers

Revenue growth (Y1)6.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin24.0%
Years to target margin4
Sales-to-capital1.60
Beta1.00
Failure probability1.0%
Cost of capital (WACC)9.2%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF4.50B
PV of terminal value5.23B
Equity value8.41B
÷ shares → per share$114.54

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 3.88B 6.0% 21.7% 642.06M 137.19M 504.87M 462.41M
2 4.10B 5.7% 22.5% 702.69M 138.69M 564.00M 473.13M
3 4.32B 5.4% 23.2% 766.14M 139.50M 626.63M 481.45M
4 4.55B 5.2% 24.0% 832.21M 139.59M 692.62M 487.40M
5 4.77B 4.9% 24.0% 872.90M 138.91M 733.98M 473.07M
6 4.99B 4.6% 24.0% 913.15M 137.43M 775.72M 457.92M
7 5.20B 4.3% 24.0% 952.72M 135.10M 817.61M 442.06M
8 5.42B 4.1% 24.0% 991.35M 131.92M 859.43M 425.59M
9 5.62B 3.8% 24.0% 1.03B 127.87M 900.94M 408.62M
10 5.82B 3.5% 24.0% 1.06B 122.94M 941.87M 391.26M

Key risks

  • Prolonged industrial or semiconductor capex slump keeps volumes and margins depressed
  • Overpaying for acquisitions (as in recent Health & Science deals) erodes returns on capital
  • Valuation already prices in a full margin recovery, leaving little room for execution misses

Catalysts

  • Margin recovery back above 23% as volumes return and 80/20 programs take hold
  • Life-science and semiconductor end-market rebound lifting organic growth to mid-single digits

History

DatePriceIntrinsicMoSRating
2026-11-17$233.57 $114.54 -51.0% HOLD
2026-08-10$234.46 $81.60 -65.2% SELL
2026-06-23$221.17 $84.76 -61.7% SELL